PBAC's latest decision on Dapagliflozin with sitagliptin: Recommended with restriction (2024). Considered for Treatment of patients with Type 2 diabetes mellitus with inadequate response to dual therapy with metformin and either a SGLT2 inhibitor or a DPP4 inhibitor, as triple therapy in combination with metformin.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adults with Type 2 diabetes mellitus inadequately controlled with dual oral combination therapy with metformin and a DPP4 inhibitor or SGLT2 inhibitor, with HbA1c >7% or blood glucose >10 mmol/L in >20% of tests over 2 weeks.
Therapy area
Endocrinology
Line of therapy
Third-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
dapagliflozin 10 mg and sitagliptin 100 mg given individually
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design. Economic model compares FDC against individual components on a cost basis only.